Completed PHASE1 INTERVENTIONAL NCT00251797

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors.

Sponsor: University of New Mexico

Conditions Brain and Nervous System Cancer

Updated 5 times since 2017 Last updated: Jan 6, 2010 Started: Mar 31, 2000 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Brain and Nervous System and Cancer, this trial is completed. The trial is conducted by University of New Mexico and has accumulated 5 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of New Mexico

Data source: University of New Mexico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Albuquerque, United States